Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Investment Income: 2020-2024

Historic Non Operating Investment Income for Tango Therapeutics (TNGX) over the last 3 years, with Mar 2024 value amounting to -$443,000.

  • Tango Therapeutics' Non Operating Investment Income fell 129.45% to -$443,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $1.9 million, marking a year-over-year increase of 60.79%. This contributed to the annual value of $150,000 for FY2024, which is 96.14% down from last year.
  • Latest data reveals that Tango Therapeutics reported Non Operating Investment Income of -$443,000 as of Q1 2024, which was down 151.10% from $867,000 recorded in Q4 2023.
  • Tango Therapeutics' 5-year Non Operating Investment Income high stood at $1.5 million for Q1 2023, and its period low was -$2.6 million during Q1 2022.
  • Moreover, its 3-year median value for Non Operating Investment Income was $684,000 (2023), whereas its average is $56,444.
  • Per our database at Business Quant, Tango Therapeutics' Non Operating Investment Income crashed by 17,733.33% in 2022 and then surged by 264.24% in 2023.
  • Over the past 5 years, Tango Therapeutics' Non Operating Investment Income (Quarterly) stood at -$9,000 in 2020, then tumbled by 8,288.89% to -$755,000 in 2021, then skyrocketed by 252.45% to $1.2 million in 2022, then dropped by 24.67% to $867,000 in 2023, then plummeted by 129.45% to -$443,000 in 2024.
  • Its Non Operating Investment Income stands at -$443,000 for Q1 2024, versus $867,000 for Q4 2023 and $836,000 for Q3 2023.